By Sabela Ojea
INmune Bio said its XPro1595 inhibitor has demonstrated remyelination, a natural process that restores myelin, in an animal model of demyelinating disease.
The clinical-stage company said the multi-year study, published in a seminal paper in the journal Cell Reports, has implications for many central nervous system diseases such as Alzheimer's.
Myelin is necessary for fast and efficient communication between neurons, the company said.
INmune expects to report top-line cognitive results of an ongoing blinded randomized Phase II in early Alzheimer disease patients in the first half of 2025.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
October 24, 2024 15:25 ET (19:25 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.